Richard Scott Struthers - 16 Mar 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
16 Mar 2026
Net transactions value
-$821,513
Form type
4
Filing time
18 Mar 2026, 17:05:33 UTC
Previous filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Struthers Richard Scott President & CEO, Director C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 18 Mar 2026 0001746298

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale $489,704 -13,196 -3.1% $37.11 413,563 16 Mar 2026 Direct F1, F2
transaction CRNX Common Stock Sale $331,809 -8,785 -2.1% $37.77 404,778 16 Mar 2026 Direct F1, F3
holding CRNX Common Stock 661,205 16 Mar 2026 By Family Trust 1
holding CRNX Common Stock 106,000 16 Mar 2026 By Family Trust 2
holding CRNX Common Stock 110,000 16 Mar 2026 By Family Trust 3
holding CRNX Common Stock 100,000 16 Mar 2026 By Family Trust 4
holding CRNX Common Stock 1,000 16 Mar 2026 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.11 per share. The range of sales prices on the transaction date was $36.42 to $37.38 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F3 The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $37.77 per share. The range of sales prices on the transaction date was $37.42 to $38.23 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.